Dallas and Austin are part of a worldwide clinical trial underway to find a more effective treatment to lower the recurrence of melanoma or high-risk skin cancer. It involves a highly advertised drug ...

(Reuters) - An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine ...

Moderna and Merck's experimental cancer vaccine, when used in combination with Merck's blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin ...

Moderna on Thursday announced that an experimental cancer vaccine it is developing with Merck — when combined with the latter’s Keytruda immunotherapy — has been proven in a clinical trial to cut the ...

Moderna and Merck's experimental cancer vaccine, used in combination with Merck's Keytruda, reduced the risk of the most deadly form of skin cancer spreading to other parts of the body in a clinical ...

The Food and Drug Administration is due to make an approval decision on injectable Keytruda by mid-September in a move that could bolster Merck's biggest franchise and downtrodden Merck stock.

The FDA approved a new drug Thursday that could change the way melanoma, the deadliest form of skin cancer, is treated. The drug, Keytruda, was considered a breakthrough and approved after it was ...

The vaccine could win regulatory approvals and launch in some countries as early as 2025, Moderna CEO Stephane Bancel said on CNBC's "Squawk Box" on Thursday. Shares of Moderna jumped more than 10% in ...